Ketamine Infusion for Treatment-resistant Major Depressive Disorder
Launched by MASSACHUSETTS GENERAL HOSPITAL · Apr 19, 2012
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
Patients will undergo two weeks of prospective observation, they will then receive ketamine IV 0.5mg/kg over 45 minutes as augmentation of their ongoing antidepressant regimen; after three infusions this dose will be increased increase to 0.75 mg/kg in non-responders. The schedule of administration will be twice a week for 3 weeks. After this phase, the patient will be followed with assessments every two weeks for three months.
Total duration of the study is 5 months.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Outpatients with severe treatment-resistant MDD
- • Currently depressed
- • Currently under regular psychiatric care
- • On an aggressive antidepressant regimen, stable for 4 weeks
- Exclusion Criteria:
- • No history of other major psychiatric illnesses, including bipolar disorder
- • No history of psychosis
- • No history of drug abuse
- • No major medical illness or unstable medical conditions
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Cristina Cusin, MD
Principal Investigator
MGH Department of Psychiatry
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials